These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33240257)

  • 21. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
    Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
    Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine.
    Wu JQ; Barabé ND; Chau D; Wong C; Rayner GR; Hu WG; Nagata LP
    Vaccine; 2007 May; 25(22):4368-75. PubMed ID: 17467858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a Western Equine Encephalitis recombinant E1 protein for protective immunity and diagnostics.
    Das D; Gares SL; Nagata LP; Suresh MR
    Antiviral Res; 2004 Nov; 64(2):85-92. PubMed ID: 15498603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants.
    Poland JD; Cropp CB; Craven RB; Monath TP
    J Infect Dis; 1990 May; 161(5):878-82. PubMed ID: 2324539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
    Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
    J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
    Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
    Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.
    Pan SC; Hsieh SM; Lin CF; Hsu YS; Chang M; Chang SC
    Vaccine; 2019 Mar; 37(14):1994-2003. PubMed ID: 30837170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A field study of persistence of antibodies in California horses vaccinated against western, eastern, and Venezuelan equine encephalomyelitis.
    Vanderwagen LC; Pearson JL; Franti CE; Tamm EL; Riemann HP; Behymer DE
    Am J Vet Res; 1975 Nov; 36(11):1567-71. PubMed ID: 1190598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
    Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
    Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
    Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
    Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.